Key result
Corydaline inhibits EV71 replication in vitro by suppressing COX-2 expression and JNK/P38 MAPK phosphorylation.
Why the study?
Does corydaline inhibit EV71 replication in vitro?
Does corydaline inhibit EV71 replication in vitro?
Corydaline demonstrates anti-EV71 activity in vitro by suppressing COX-2 expression and MAPK phosphorylation, suggesting potential as a lead compound for new antiviral agents.
Enterovirus 71 (EV71) is a huge threat to the worldwide public health and there is no approved antiviral drug for EV71-induced disease therapy. Corydaline exists antiallergic and antinociceptive activities, but the anti-EV71 activity of corydaline is still not reported. In this study, corydaline could suppress the expression of viral structural and non-structural proteins. Furthermore, corydaline inhibits EV71 replication by suppressing the COX-2 expression and the phosphorylation of JNK MAPK and P38 MAPK but not ERK MAPK in vitro. Based on these findings, corydaline could be a potential lead or supplement for the development of new anti-EV71 agents in the future.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2017) studied Enterovirus 71 (EV71) infection. Corydaline was evaluated on EV71 replication and viral protein expression. Corydaline inhibits Enterovirus 71 replication in vitro by suppressing COX-2 expression and the phosphorylation of JNK and P38 MAPK.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: